We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

35 hedge funds and large institutions have $20.6M invested in Aligos Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.82% more ownership

Funds ownership: 45.68% → 51.51% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

13% less funds holding

Funds holding: 40 → 35 (-5)

21% less capital invested

Capital invested by funds: $26.2M → $20.6M (-$5.58M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
9
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$1.64M
2
UBS Group
UBS Group
Switzerland
+$278K
3
Renaissance Technologies
Renaissance Technologies
New York
+$114K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$83.3K
5
QC
Quadrature Capital
United Kingdom
+$82.1K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$848K
2
Two Sigma Investments
Two Sigma Investments
New York
-$437K
3
Verition Fund Management
Verition Fund Management
Connecticut
-$397K
4
Jane Street
Jane Street
New York
-$226K
5
DS
DRW Securities
Illinois
-$111K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$7.06K +$7.21K +950 New
VGA
27
Vanguard Global Advisers
Pennsylvania
$6.95K +$7.1K +936 New
Wells Fargo
28
Wells Fargo
California
$5.2K -$6.07K -800 -53%
JP Morgan Chase
29
JP Morgan Chase
New York
$4.42K +$2.79K +368 +120%
Morgan Stanley
30
Morgan Stanley
New York
$1.62K -$17.5K -2,302 -91%
FFO
31
Fortitude Family Office
Arizona
$505 +$516 +68 New
TRCT
32
Tower Research Capital (TRC)
New York
$483 +$197 +26 +67%
SS
33
SBI Securities
Japan
$193 – – –
EWP
34
Elevation Wealth Partners
California
$30 – – –
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$22 – – –
Jane Street
36
Jane Street
New York
– -$226K -24,293 Closed
A
37
AlphaQuest
New York
– -$129K -13,876 Closed
Two Sigma Advisers
38
Two Sigma Advisers
New York
– -$121K -13,000 Closed
DS
39
DRW Securities
Illinois
– -$111K -11,950 Closed
HF
40
HRT Financial
New York
– -$106K -11,374 Closed
NAM
41
NorthCrest Asset Manangement
Minnesota
– -$84.1K -10,000 Closed
Fidelity Investments
42
Fidelity Investments
Massachusetts
– -$46.3K -4,972 Closed
SSG
43
Summit Securities Group
New York
– -$4.66K -500 Closed
TCM
44
Triumph Capital Management
Colorado
– -$1.26K -135 Closed
Citigroup
45
Citigroup
New York
– -$9 -1 Closed
1
2

ALGS Hedge Fund Activity: Q1 2026 in Review

35 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2026, worth a combined $20.6M — down 21% from $26.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ALGS and 7 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.

The largest buyer was Bank of America, adding an estimated $1.64M. The largest seller was Woodline Partners, cutting an estimated $848K.

  • 35 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2026, down from 40 in Q4 2025.
  • Funds reported $20.6M of Aligos Therapeutics stock for Q1 2026, down 21% quarter-over-quarter.
  • 7 funds opened new Aligos Therapeutics positions in Q1 2026 and 10 closed out, a net change of -3 holders.
  • The largest Aligos Therapeutics buyer in Q1 2026 was Bank of America, an estimated $1.64M added.
  • The largest Aligos Therapeutics seller in Q1 2026 was Woodline Partners, an estimated $848K sold.

Based on aggregated 13F filings for Q1 2026.